Liraglutide improves metabolic disturbances in antipsychotic ‐treated schizophrenia patients

A 16‐week study of patients with schizophrenia who were receiving clozapine or olanzapine has found that the glucagon‐like peptide‐1 (GLP‐1) receptor agonist liraglutide significantly improved glucose tolerance, body weight, and cardiometabolic disturbances compared with placebo. The patients in the study were overweight or obese and were considered prediabetic. Study results were published online June 10 in JAMA Psychiatry.
Source: The Brown University Psychopharmacology Update - Category: Psychiatry Tags: Schizophrenia Treatment Source Type: research